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Time-Dependent Cardiac Chimerism in Gender-Mismatched Heart Transplantation Patients
To the Editor: Recently, the view of the heart as a terminally
differentiated organ has been challenged. Cardiomyocytes of re-
cipient origin have been detected in patients who have received
gender-mismatched heart (1,2), bone marrow (3–5), and periph-
eral blood stem cell (4) transplants and have been shown to be able
to proliferate (1). However, the numbers of newly formed cells in
these studies were extremely variable. One possible explanation was
the interval between transplantation and tissue examination (2). We
hypothesized that cardiac regeneration might increase rather than
decrease over time because after cardiac transplantation and possibly
in cardiac disease in general, myocyte loss and regeneration might
require some time. To test this hypothesis, we performed a longitu-
dinal chimerism study on gender-mismatched male transplant recip-
ients using immunostaining and fluorescence in situ hybridization
(FISH) to detect recipient cells. Moreover, the proliferative capacity
of cardiomyocytes in early and later obtained biopsy samples was
assessed by Ki67 expression.
Serial right ventricular myocardial biopsy samples (n 10) were
routinely obtained from patients after gender-mismatched cardiac
transplantation during normal post-transplantation follow-up.
The first biopsy samples were obtained at 6 to 14 days, and other
biopsy samples at 3.5 to 13 months after transplantation. Three
men with male cardiac allograft transplants as well as 2 women
with gender-matched heart transplants were taken as positive and
negative controls for the detection of X and Y chromosomes,
respectively. Immunosuppressive medication was based on stan-
dard protocols. Age at transplantation, interval between transplan-
tation and biopsy examination, and acute rejection according to the
International Society for Heart and Lung Transplantation scale are
shown in Table 1. All biopsy samples were fixed in 4% buffered
formalin, embedded in paraffin, and cut in 6-m sections.
Immunostaining for cardiomyocytes was performed using anti-
bodies against alpha-sarcomeric actin (Sigma, St. Louis, Missouri)
and myoglobin (Dako, Glostrup, Denmark). Coupling between
cardiomyocytes was assessed by connexin 43 immunostaining
(Sigma). To evaluate proliferative activity in cardiomyocytes, Ki67
(clone MIB-1, Dako) immunostaining was combined with immu-
nostaining for alpha-sarcomeric actin.
For sex chromosome detection, FISH was performed using
probes DXZ1 (Oncor, Illkirch, France) for X chromosome and
Y3.4 for Y chromosome. Immunostaining and FISH protocols
were performed as described previously (2).
Sections were inspected with a Nikon E600 fluorescence mi-
croscope (Nikon Europe, Düsseldorf, Germany) and recorded by a
Nikon DXM 1200 digital camera. In total, 47,530 nuclei have
been examined. The chimerism value was evaluated by dividing the
number of Y chromosome-positive cells by the total number of
cardiomyocytes. The regeneration rate was obtained by dividing
the chimerism value by the hybridization efficiency, which corre-
sponds to the number of Y chromosome-positive cardiomyocytes
in the positive controls.
In the positive controls, 52.8% of the cardiomyocytes showed a
Y chromosome. Consequently, the regeneration rate was about
two times higher than the chimerism rates. In the negative
controls, no Y chromosomes were found.
Cardiomyocytes containing Y chromosomes were detected in
all biopsy samples obtained from gender-mismatched trans-
plantation patients, in the early as well as in the late cases.
Connexin 43 was expressed even in the cardiomyocytes of early
biopsy samples (Fig. 1A). The average value of chimeric cardio-
myocytes was 0.154  0.043% (mean  SEM), corresponding
well to the value of our previous study (2). Nevertheless, we
observed an increase in cardiomyocyte chimerism in the biopsy
samples obtained at later time points in every individual patient
(Fig. 1B). Taken together, chimerism increased from 0.052 
0.01% in the early biopsy samples to 0.256  0.053% in the late
biopsy samples (p  0.02, paired t test) (Fig. 1C), which
corresponds to an increase of from 0.098  0.018% to 0.485 
0.101% newly formed cardiomyocytes taken into consideration the
hybridization efficiency. Cell fusions were excluded using probes
for both sex chromosomes.
Expression of Ki67 was very rare in the early biopsy samples as
well as in the late ones. Altogether, only five cardiomyocyte nuclei
expressed Ki67 (Figs. 1D and 1F), indicating that 0.031% of all
cardiomyocytes showed evidence for proliferation. Only one of five
positive nuclei originated from the late biopsy of a patient; the
others were derived from the early biopsy of another patient. Eight of
10 biopsy samples did not show any proliferating cardiomyocytes. The
chromosomal status of the Ki67-positive nuclei was non-uniform.
Table 1. Information About Patients and Biopsies
Patient Biopsy
Age at
HTx
Interval HTx
to Biopsy
Time Point of Biopsy
Relative to HTx
Acute Rejection in
Current Biopsy
1 1a 56 13 days Early ISHLT 1A
1 1b 56 13 months Late ISHLT 1A
2 2a 42 11 days Early ISHLT 0
2 2b 42 3.5 months Late ISHLT 1A
3 3a 51 6 days Early ISHLT 0
3 3b 51 11 months Late ISHLT 0
4 4a 58 12 days Early ISHLT 0
4 4b 58 12 months Late ISHLT 1A
5 5a 60 14 days Early ISHLT 0
5 5b 60 3.5 months Late ISHLT 3A
HTx  heart transplantation; ISHLT  International Society for Heart and Lung Transplantation.
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Three of five nuclei expressed a Y chromosome (Fig. 1E), the others
expressed two X chromosomes (Fig. 1G).
The mean size of host- and graft-derived cardiomyocytes in
both early and later obtained biopsy samples did not differ
significantly. However, Ki67-positive cardiomyocytes had a signif-
icant smaller cross-sectional area than Ki67-negative donor- or
graft-derived cardiomyocytes (133.68  39.22 m2 vs. 533.69 
22.68 m2; p  0.001 Mann-Whitney test).
It was suggested that cardiac regeneration initially increases
after transplantation, but decreases after several months (2) because
resettlement of newly formed cardiomyocytes might be a tempo-
rary effect, followed by apoptosis, a well-known mechanism in the
pathogenesis of heart failure (6). However, the presented longitu-
dinal study in living patients shows in fact a significant increase in
regeneration rates over time, corresponding to another recently
published autopsy study that showed a slight amount of chimeric
cardiomyocytes after bone marrow transplantation (4). Therefore,
cardiac regeneration over time might gradually substitute damaged
cardiomyocytes after cardiac transplantation.
Because Ki67-positive cardiomyocytes tend to be smaller than
non-proliferating myocytes, they are thought to be young cells that
might arise from stem cell differentiation (7). Consequently, if
newly formed cardiomyocytes were present in the biopsy samples
obtained a few days after transplantation, they would be expected
to express Ki67 rather than donor-derived cardiomyocytes, in
which the probability to be terminally differentiated is much
higher. Furthermore, in cardiac transplants, temporary ischemia
could be a stimulus for proliferation. Indeed, 3 of 5 Ki67-positive
cardiomyocytes were of recipient origin. However, 8 of 10 biopsy
samples did not show any proliferating cardiomyocytes, and overall
expression in all biopsy samples was low (0.031%). Size and shape
of host-derived cardiomyocytes were also undistinguishable from
donor-derived cells. These results indicate that most of the newly
formed cardiomyocytes are already terminally differentiated or at
Figure 1. (A) The biopsy section of a female cardiac allograft 11 days after transplantation into a male recipient. Bright green bands marked by arrowheads
indicate connexin 43 immunostaining, dark green areas represent autofluorescence. The cardiomyocyte nucleus, marked by an arrow, shows a red
fluorescence in situ hybridization (FISH) signal, representing the Y chromosome. Bar  10 m. (B, C) Comparison of sex chromosome chimerism in
biopsy samples obtained early and late after heart transplantation (HTx). (B) Early and late chimerism values of every patient. (C) Comparison of average
chimerism values (mean  SEM) of all patients in early and late biopsy samples; p  0.02 (paired t test). (D, F) Sections after combined immunostaining
with Ki67 and alpha-sarcomeric actin. Red areas indicate alpha-sarcomeric actin, nuclei are stained blue by 4=,6-Diamidino-2-phenylindole. Green-stained
nuclei indicate Ki67 immunostaining. Proliferating cardiomyocyte nuclei are marked by arrows. (E, G) The same sections as D and F, respectively, after
FISH. Dark red areas represent cytoplasmatic autofluorescence. Sex chromosomes are expressed by green (X chromosomes) and red (Y chromosomes)
signals, respectively. Bars  10 m.
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least did not proliferate at the time examined. In addition, even
newly formed cardiomyocytes in early biopsy samples expressed
connexin 43, providing evidence for a functional coupling to
adjacent myocytes in the transplanted myocardial tissue. The
origin of the newly formed cells might be the bone marrow (3–5).
However, because in orthotopic cardiac transplantation the
atrial stumps of the donors remain in the thorax, host-derived
resident cardiac progenitor cells might also contribute to cardiac
regeneration.
Recapitulating, our results illustrate a small but persistent
increase in cardiac regeneration. This raises hope that this process
could be accelerated and therefore used therapeutically, e.g., by
growth factor application or autologous stem cell transplantation.
However, the number of regenerated cells is still low, and studies
on transplanted myocardium after repetitive rejections or myocar-
dial infarctions will show the biological relevance of cardiac
chimerism.
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Letters to the Editor
Measuring Effects of
Antiatherosclerotic Therapies
Corti et al. (1) found no difference in vessel wall area measured by
magnetic resonance imaging (MRI) between simvastatin 80 mg
and 20 mg daily over 18 months of follow-up. This might have
been due to the small sample size of 51 subjects, but it also was
probably partly due to the method of measurement.
It is important to understand that methods for measuring athero-
sclerosis give biologically distinct phenotypes (2). Traditional risk
factors account for 53% of variance (R2) of carotid plaque area, but
only 13% of carotid stenosis measured by Doppler velocities, and
only 15% to 17% of intima-media thickness (IMT). Including
IMT in a measurement of “atherosclerosis” introduces the noise of
the medial hypertrophy that is due to blood pressure. For maxi-
mum carotid IMT, sample sizes are from 468 per group for a 30%
effect size, to 30 per group for a 100% effect size over 3 years (3).
Sensitivity of measurements to effects of therapy also depends
on the location and method of the measurement. Carotid plaques
grow along the artery 2.4 times faster than they thicken (4). Most
carotid plaques are focal, with a proximal and distal end, which can
progress or regress, and this change can be captured by measuring
plaque area (5). Plaque volume is even more sensitive to effects of
treatment. We recently found that a sample of 20 patients per group
was sufficient to detect regression of plaque with high-dose atorva-
statin versus placebo in three months (6). Because coronary plaques
are diffuse, without a proximal and distal end, change in coronary
plaque volume reduces to a change in thickness. Therefore, sample
sizes and duration of therapy required to show effects of treatment
with intravascular ultrasound are substantially larger: in the
REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid-
Lowering) (7) study, 654 patients were followed 18 months to show
a difference between high-dose atorvastatin and pravastatin.
Finally, investigators wishing to measure effects of antiathero-
sclerotic therapy would be well served by measuring carotid plaque
volume using three-dimensional ultrasound.
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